

Outline of Initial Listing Issue

\* The Company revised data for the following items effective Jun. 19, 2023: Public Offering (the breakdown of the numbers of shares to be issued through domestic and international offerings). The revisions are underlined.

Company Name	Noile-Immune Biotech Inc.
Scheduled Listing Date	Jun. 28, 2023
Market Section	Growth Market
Current Listed Market	N/A
Name and Title of Representative	TAMADA Koji, President & CEO
Address of Main Office	2-12-10 Shiba-Daimon, Minato-ku Tokyo, 105-0012 Tel. +81-3-5843-7819
(Closest Point of Contact)	(Same as above)
Home Page	<a href="https://www.noile-immune.com/en.html">https://www.noile-immune.com/en.html</a>
Date of Incorporation	Apr. 16, 2015
Description of Business	Development of novel cancer immunotherapy including CAR-T cell therapy
Category of Industry / Code	Pharmaceutical / 4893(ISIN JP3759560000)
Authorized Total No. of Shares to be Issued	155,800,000 shares
No. of Issued Shares	39,579,865 shares (As of May 25, 2023)
No. of Issued Shares (incl. treasury shares) at the Time of Listing	43,202,865 shares (Note 1) The number includes newly issued shares issued through the public offering. (Note 2) The number could increase as a result of the exercise of share options, etc.
Capital	JPY 2,787,552 thousand (As of May 25, 2023)
No. of Shares per Share Unit	100 shares
Business Year	From Jan. 1 to Dec. 31
General Shareholders Meeting	Within 3 months after the end of the business year
Record Date	Dec. 31
Record Date of Surplus Dividend	Jun. 30 and Dec. 31
Transfer Agent	Mitsubishi UFJ Trust and Banking Corporation
Auditor	Deloitte Touche Tohmatsu LLC
Managing Trading Participant	SMBC Nikko Securities Inc.

(Reference Translation)

<Overview of Public Offering / Secondary Offering >

Public Offering / Secondary Offering	Public Offering (Newly Issued Shares) (Note) The number of shares scheduled to be issued through the public offering is <u>1,019,000</u> shares and <u>2,604,000</u> shares respectively for the domestic and international offerings.	3,623,000 shares
	Secondary Offering (Placement by over-allotment scheme)	543,400 shares
Offering Price Determination Method	Book-building method	
Provisional Conditions Determination Date	Jun. 12, 2023	
Book-building Period	Jun. 13, 2023 to Jun. 16, 2023	
Offering Price Determination Date	Jun. 19, 2023	
Subscription Period	Jun. 20, 2023 to Jun. 23, 2023	
Payment Date	Jun. 27, 2023	
Settlement Date	Jun. 28, 2023	
Principal Underwriting Participants	SMBC Nikko Securities Inc. SBI SECURITIES Co.,Ltd. Nomura Securities Co.,Ltd. Mizuho Securities Co., Ltd. TOYO SECURITIES CO.,LTD. IwaiCosmo Securities Co.,Ltd. Akatsuki Securities,Inc. Marusan Securities Co.,Ltd. Kyokuto Securities Co., Ltd. Monex, Inc. Okasan Securities Co., Ltd.	

(Note 1) Tokyo Stock Exchange, Inc. approves new listings based on the results of the examination by Japan Exchange Regulation.

(Note 2) The “Initial Listing Application Securities Report (Part I)” (only in Japanese) of the company is available on the JPX official website. Please refer to such release for details.

(Note 3) Buy and sell market orders for this issue are prohibited in transactions carried out up to and including the initial price determination date.